高龄下呼吸道感染患者的替考拉宁血药浓度监测及安全性评价

Clinical study of the safety in elderly patients with lower respiratory infections and therapeutic drug monitoring of teicoplanin

目的探讨替考拉宁在高龄下呼吸道感染患者中的血药浓度与临床疗效、不良反应之间的关系。方法高龄下呼吸道感染病例52例，用替考拉宁治疗5—24d，观察患者疗效、给药前后肝肾功能指标及不良反应情况；监测患者替考拉宁的谷浓度。结果替考拉宁的谷浓度为（17．1±10．1）mg·L^-1，治疗有效组和无效组在血药浓度等方面差异无统计学意义；给药前后肝、肾功能指标差异无统计学意义。结论替考拉宁在治疗下呼吸道感染患者时，血药浓度与疗效之间未见显著相关性，临床应用时应在血药浓度的监测下行个体化治疗。

AIM To study the relationship between plasma concentration and clinical effects, adverse drug reactions of teicoplanin in elderly patients with lower respiratory infections. METHODS All 52 elderly patients with lower respiratory infections were treated by teicoplanin with 5 - 24 days and the effects were evaluated. The hepatic and renal functional parameters were collected before and after treatment. The plasma concentration in each patient was monitored. RESULTS The trough concentration of teicoplanin was （17.1±10.1）mg·L^-1. There were no relationships between the drug concentration and efficacy. And the hepatic and renal functional parameters were not changed before and after treatment. CONCLUSION Teicoplanin plasma concentrations do not correlate with efficacy in elderly patients with lower respiratory infections and therapeutic drug monitoring is needed to get individual therapy.